Pulse Biosciences (NASDAQ:PLSE) Shares Gap Up on Insider Buying Activity

Pulse Biosciences, Inc. (NASDAQ:PLSE)’s stock price gapped up before the market opened on Monday after an insider bought additional shares in the company. The stock had previously closed at $17.65, but opened at $18.51. Pulse Biosciences shares last traded at $19.25, with a volume of 35,220 shares trading hands.

Specifically, Director Robert W. Duggan purchased 56,054 shares of the business’s stock in a transaction on Wednesday, December 11th. The shares were acquired at an average price of $17.35 per share, with a total value of $972,536.90. Following the acquisition, the director now directly owns 42,228,057 shares in the company, valued at approximately $732,656,788.95. The trade was a 0.13 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Wall Street Analysts Forecast Growth

Separately, StockNews.com raised shares of Pulse Biosciences to a “sell” rating in a report on Thursday, December 12th.

Pulse Biosciences Price Performance

The business’s fifty day simple moving average is $17.74 and its 200-day simple moving average is $16.50.

Pulse Biosciences (NASDAQ:PLSE) last announced its quarterly earnings results on Wednesday, October 30th. The company reported ($0.21) earnings per share (EPS) for the quarter. During the same period last year, the company earned ($0.19) EPS.

Institutional Investors Weigh In On Pulse Biosciences

Large investors have recently added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. increased its position in shares of Pulse Biosciences by 193.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 148,114 shares of the company’s stock valued at $2,598,000 after buying an additional 97,565 shares during the period. Creative Planning increased its position in shares of Pulse Biosciences by 113.9% during the third quarter. Creative Planning now owns 21,910 shares of the company’s stock valued at $384,000 after buying an additional 11,667 shares during the period. Cetera Advisors LLC purchased a new position in shares of Pulse Biosciences during the first quarter valued at about $109,000. Price T Rowe Associates Inc. MD purchased a new position in shares of Pulse Biosciences during the first quarter valued at about $88,000. Finally, Quest Partners LLC purchased a new position in shares of Pulse Biosciences during the second quarter valued at about $91,000. Institutional investors own 76.95% of the company’s stock.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.